Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jenna L. Koliani-Pace"'
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083dd325756fdb07317c52afa6118590
https://doi.org/10.1016/j.cgh.2020.10.003
https://doi.org/10.1016/j.cgh.2020.10.003
Autor:
Jenna L. Koliani-Pace, Corey A. Siegel
Publikováno v:
Gastrointestinal Endoscopy Clinics of North America. 29:395-404
Both Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) that can lead to progressive irreversible bowel damage. Selecting the most appropriate therapy for patients is a challenge because not all patients diagnosed with IBD h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c90a5af4e1a10a5bbc0cfe50f3118638
https://doi.org/10.1016/j.giec.2019.02.003
https://doi.org/10.1016/j.giec.2019.02.003
Autor:
Bruce E. Sands, Robert Hirten, Keith Sultan, David Faleck, Jenna L. Koliani-Pace, Shannon Chang, Michelle Luo, Eugenia Shmidt, David Hudesman, William J. Sandborn, Youran Gao, Parambir S. Dulai, Bo Shen, Monika Fischer, Preeti Shashi, Dana J. Lukin, A Weiss, Sunanda V. Kane, Gursimran Kochhar, Jiao Yang, Arun Swaminath, Joseph Meserve, Satimai Aniwan, Edward V. Loftus, Siddharth Singh, Adam Winters, Matthew Bohm, Shreya Chablaney, Zhongwen Huang, Sashidhar Varma, Nitin Gupta, Brigid S. Boland, Karen Lasch, Jean-Frederic Colombel, Corey A. Siegel
Publikováno v:
Inflammatory Bowel Diseases
Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7cf99eb2d4619d6efbde3a95793bbd
https://doi.org/10.1093/ibd/izz071
https://doi.org/10.1093/ibd/izz071
Autor:
Monika Fischer, Arun Swaminath, Joseph Meserve, Khadija Chaudrey, Nitin Gupta, David Faleck, Corey A. Siegel, Eugenia Shmidt, Dana J. Lukin, William J. Sandborn, Bo Shen, Niels Vande Casteele, Matthew Bohm, Michelle Luo, Gursimran Kochhar, Jenna L. Koliani-Pace, David Hudesman, Siddharth Singh, Edward V. Loftus, Sunanda V. Kane, Keith Sultan, Shannon Chang, Robert Hirten, Parambir S. Dulai, Justin Hartke, Jean-Frederic Colombel, Karen Lasch, Morris Barocas, Brigid S. Boland, Sashidhar Sagi, Prianka Chilukuri, Bruce E. Sands
Publikováno v:
Inflammatory Bowel Diseases. 24:2461-2467
Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) of a prospectively maintain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7bf71d58fdc07d832d4e140e7a270f8
https://doi.org/10.1093/ibd/izy171
https://doi.org/10.1093/ibd/izy171
Autor:
Brian E. Lacy, Jenna L. Koliani-Pace
Publikováno v:
Current Treatment Options in Gastroenterology. 15:126-134
Chronic constipation (CC) is a highly prevalent disorder encountered by health care providers of all specialties. The diagnosis can be confidently made by taking a careful history, evaluating for warning signs and symptoms, performing an examination,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::775d877d5cdcb8c007d1405a53a3ad09
https://doi.org/10.1007/s11938-017-0118-2
https://doi.org/10.1007/s11938-017-0118-2
Autor:
Anil Nayyar, Jenna L. Koliani-Pace, Kerry Jo Lee, Eric D. Shah, Corey A. Siegel, Elliot Coburn
Publikováno v:
Aliment Pharmacol Ther
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, poorly treatable malignancy associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era of step-up therapy, before earlier use of biologics or combination thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e08831dc5295ed8d4e5d3fa7e3954071
https://pubmed.ncbi.nlm.nih.gov/31990422
https://pubmed.ncbi.nlm.nih.gov/31990422
Autor:
Shannon Chang, Dana J. Lukin, Maria Rosario, Bo Shen, David Faleck, Arun Swaminath, Joseph Meserve, Satimai Aniwan, Ryan C. Ungaro, David Hudesman, A Weiss, Brigid S. Boland, Gursimran Kochhar, Robert Hirten, Nitin Gupta, Vipul Jairath, Sashidhar Varma, Karen Lasch, Eugenia Shmidt, Preeti Shashi, Siddharth Singh, Matthew Bohm, Brian G. Feagan, Sunanda V. Kane, Bruce E. Sands, Shreya Chablaney, Jean-Frederic Colombel, Jenna L. Koliani-Pace, Edward V. Loftus, Corey A. Siegel, Adam Winters, John T. Chang, Charlie Cao, Keith Sultan, Leonardo Guizzetti, Parambir S. Dulai, William J. Sandborn, Youran Gao, Monika Fischer, Niels Vande Casteele
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 18, iss 13
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 18, iss 13
Background & aimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf7f18370dafe0ee9e71636303a3071
https://doi.org/10.1016/j.cgh.2020.02.010
https://doi.org/10.1016/j.cgh.2020.02.010
Publikováno v:
Gastrointestinal Endoscopy. 85:666-668
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::732b7e2de224780626f1241bf4e97e58
https://doi.org/10.1016/j.gie.2017.01.003
https://doi.org/10.1016/j.gie.2017.01.003
Autor:
Karen Lasch, Diana Whitehead, Jenna L. Koliani-Pace, David Hudesman, Brian G. Feagan, Prianka Chilukuri, Gursimran Kochhar, Robert Hirten, Siddharth Singh, Malav P. Parikh, John T. Chang, Guangyong Zou, Leah Katta, Eugenia Shmidt, Justin Hartke, Sunanda V. Kane, Charlie Cao, Matthew Bohm, Farhad Peerani, Bruce E. Sands, Jean-Frederic Colombel, Edward V. Loftus, Keith Sultan, Dana J. Lukin, Vipul Jairath, Bo Shen, William J. Sandborn, Jesus Rivera-Nieves, Neeraj Narula, Adam Winters, Corey A. Siegel, Arun Swaminath, Joseph Meserve, Parambir S. Dulai, Khadija Chaudrey, Brigid S. Boland
Background & Aims As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely to respond to different therapies. We created and validated a scoring system to identify patients with Croh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b86b5a69518157f3f7901d89bbed3f
https://europepmc.org/articles/PMC6419724/
https://europepmc.org/articles/PMC6419724/
Autor:
Dana J. Lukin, David Faleck, Adam Winters, Edward V. Loftus, Michelle Luo, Leah Katta, Robert Hirten, Sunanda V. Kane, Justin Hartke, Diana Whitehead, Khadija Chaudrey, Siddharth Singh, Monika Fischer, Keith Sultan, Brigid S. Boland, Corey A. Siegel, Arun Swaminath, Joseph Meserve, Bo Shen, Malav P. Parikh, Gursimran Kochhar, Bruce E. Sands, Parambir S. Dulai, Nitin Gupta, Farhad Peerani, Jenna L. Koliani-Pace, Morris Barocas, Eugenia Shmidt, William J. Sandborn, Neeraj Narula, Jean-Frederic Colombel, Shannon Chang, Karen Lasch, Prianka Chilukuri, Sashidhar Sagi, David Hudesman, Matthew Bohm
Publikováno v:
The American Journal of Gastroenterology
OBJECTIVES: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment. METHODS: Retrospective review (May 2014 – December 2016) of VICTORY Consortium data. Adults wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4bde4727b59e3340292a58fd38e637d
https://pubmed.ncbi.nlm.nih.gov/30390030
https://pubmed.ncbi.nlm.nih.gov/30390030